Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy.
Atzmony L, Lim YH, Hamilton C, Leventhal JS, Wagner A, Paller AS, Choate KA.
J Am Acad Dermatol. 2020 Jan;82(1):123-131. doi: 10.1016/j.jaad.2019.08.043. Epub 2019 Aug 23.
Giant porokeratosis.
Bozdağ KE, Biçakçi H, Ermete M.
Int J Dermatol. 2004 Jul;43(7):518-20. doi: 10.1111/j.1365-4632.2004.02158.x.
Porokeratosis Ptychotropica.
Liu W, Liu JW, Ma DL.
JAMA Dermatol. 2019 Jul 1;155(7):845. doi: 10.1001/jamadermatol.2019.0602.
[Linear porokeratosis].
Eicher L, Flaig MJ, Senner S, Betke M.
Hautarzt. 2020 Jul;71(Suppl 1):54-56. doi: 10.1007/s00105-020-04641-z.
Porokeratosis ptychotropica.
Tebet AC, Oliveira TG, Oliveira AR, Moriya FS, Oliveira J Filho, Cucé LC.
An Bras Dermatol. 2016 Sep-Oct;91(5 suppl 1):134-136. doi: 10.1590/abd1806-4841.20164399.
Porokeratosis.
Sehgal VN, Jain S, Singh N.
J Dermatol. 1996 Aug;23(8):517-25. doi: 10.1111/j.1346-8138.1996.tb02644.x.
Generalized Linear Porokeratosis.
Lu Y, Feng L.
J Cutan Med Surg. 2022 Nov-Dec;26(6):639. doi: 10.1177/12034754221077925. Epub 2022 Feb 8.
[Porokeratosis].
Marque M, Meunier L.
Ann Dermatol Venereol. 2012 Oct;139(10):668-76. doi: 10.1016/j.annder.2012.05.026. Epub 2012 Aug 2.
Porokeratosis: present concepts.
Sertznig P, von Felbert V, Megahed M.
J Eur Acad Dermatol Venereol. 2012 Apr;26(4):404-12. doi: 10.1111/j.1468-3083.2011.04275.x. Epub 2011 Sep 20.
Adalimumab-induced porokeratosis.
Frew JW, Parsi K.
Australas J Dermatol. 2015 Aug;56(3):e80-1. doi: 10.1111/ajd.12215.
